Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Smith Kungwankiattichai"'
Publikováno v:
Siriraj Medical Journal. 74:256-265
Objective: This study aimed to validate the sensitivity analysis of all the available formulas for their ability to differentiate between IDA and thalassemia and propose a novel formula to improve the sensitivity of all thalassemia subtypes screening
Autor:
Smith Kungwankiattichai, Ben Ponvilawan, Claudie Roy, Pattaraporn Tunsing, Florian Kuchenbauer, Weerapat Owattanapanich
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionHypomethylating agents (HMAs) seem to have a range of properties favorable to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute myeloid leukemia (AML) patients.Materials and MethodsThe Embase, MEDLINE
Autor:
Pattaraporn Tunsing, Smith Kungwankiattichai, Ben Ponvilawa, Florian Kuchenbauer, Claudie Roy, Weerapat Owattanapanich
Review question / Objective: P: Patients with AML or MDS after allo-SCT; I: Hypomethylating agents after allo-SCT; C: Observation after allo-SCT; O: Overall survival rates. Condition being studied: Hypomethylating agents (HMAs) seem to have a range o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d58dd334f1d582c5b4d6f451c66cb3c6
https://doi.org/10.37766/inplasy2021.11.0078
https://doi.org/10.37766/inplasy2021.11.0078
Publikováno v:
Hematology/Oncology and Stem Cell Therapy.
Background Matched donor (MD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the preferred choice of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients who have achieved complet
Autor:
Donald Bunjes, Patompong Ungprasert, Florian Kuchenbauer, Smith Kungwankiattichai, Weerapat Owattanapanich, Verena Wais
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 8, Iss 9, p 1437 (2019)
Journal of Clinical Medicine, Vol 8, Iss 9, p 1437 (2019)
Reduced-intensity conditioning (RIC) regimens are established options for hematopoietic stem cell transplantation (HSCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, the efficacy of RIC regimens for pati
Autor:
Smith Kungwankiattichai, BEN Ponvilawan, Claudie Roy, Pattaraporn Tunsing, Florian Kuchenbauer, Weerapat Owattanapanich
Publikováno v:
Blood. 138:3703-3703
Background: After allogeneic hematopoietic stem cell transplantation (allo-SCT), 35%-45% of patients suffer disease relapse, resulting in dismal outcomes. Several strategies have been adopted to prolong disease-free intervals. Hypomethylating agents
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0253896 (2021)
PLoS ONE
PLoS ONE
Background Hematopoietic stem cell transplantation (HSCT) is the current mainstay treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). However, tyrosine kinase inhibitors (TKI) also play a significant role in the tre
Autor:
Smith Kungwankiattichai, Weerapat Owattanapanich, Natthida Owattanapanich, Patompong Ungprasert, Theera Ruchutrakool
Publikováno v:
Clinical lymphoma, myelomaleukemia. 18(12)
Background The 2 main formulations of anthracycline used for acute myeloid leukemia (AML) induction therapy are idarubicin (IDA) and daunorubicin. Patients and Methods The present systematic review and meta-analysis compared the efficacy and toxicity